RVRandall W. Velliquette

Randall W. Velliquette

*This is an algorithmically generated author record based on publicly available information.

Randall W. Velliquette has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Sunitha Vege

    Immunohematology and Genomics Laboratory New York Blood Center Rye New York USA

    2 shared publications
  • Alastair Murray

    Department of Pediatrics, Division of Pediatric Hematology/Oncology Seattle Children's Hospital Seattle Washington USA

    1 shared publication
  • Aline Floch

    Laboratoire de Biologie Moléculaire de Référence en Immunohématologie Moléculaire Etablissement francais du sang Ile‐de‐France Creteil France

    1 shared publication
  • Aurélie Barrault

    Laboratoire de Biologie Moléculaire de Référence en Immunohématologie Moléculaire Etablissement francais du sang Ile‐de‐France Creteil France

    1 shared publication
  • Bruce S. Sachais

    Immunohematology and Genomics Laboratory New York Blood Center Enterprises Rye New York USA

    1 shared publication
  • Chloe Homich

    Immunohematology Reference Laboratory Blood Bank of Delmarva (a Division of New York Blood Center Enterprises) Newark Delaware USA

    1 shared publication

Latest Publications

  • Open Access

    A PIGG congenital disorder of glycosylation ( PIGG ‐ CDG ) variant associated with an Emm− red blood cell phenotype in a pediatric patient

    by Alastair Murray, Connie M. Westhoff, Sunitha Vege, Hallie Lee‐Stroka, Randall W. Velliquette, William J. Lane, Jillian G. Buchan, Nabiha H. Saifee, Rida A. Hasan

    Background: The high‐prevalence Emm antigen is an epitope on the GPI (glycosylphosphatidylinositol) glycolipid backbone, which anchors proteins to the cell surface. Inherited loss‐of‐function of PIGG (or PIGO ) results in the rare Emm− red cell (RBC) phenotype and is associated with congenital disorders of glycosylation (CDG). Anti‐Emm has been reported to cause clinically significant hemolytic transfusion reactions. Case Presentation: We describe a 2‐year‐old male with neurologic manifestations of CDG in whom whole‐exome sequencing (WES) identified a homozygous PIGG c.1515G>A, p.(Trp505Ter) variant. The patient had received a single RBC transfusion in infancy with no detectable alloantibodies. Serologic evaluation demonstrated an Emm− RBC phenotype. Confirmation by Sanger sequencing verified homozygosity for this PIGG loss‐of‐function variant, and family studies showed both parents and a sibling were heterozygous. Discussion: To date, eight other PIGG variants are known to underlie the Emm− phenotype; the c.1515G>A, p.(Trp505Ter) variant has not previously been shown to cause a null phenotype. Recognition of the rare Emm− phenotype in patients with CDG has important transfusion implications, including alloimmunization risk and difficulty sourcing compatible blood due to the rare occurrence and lack of typing reagents. Conclusion: This case expands the number of PIGG variants associated with the Emm− phenotype and underscores the importance of integrating the growing number of genomic diagnostic findings with transfusion medicine evaluation to guide safe transfusion management.

  • Open Access

    Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine

    by Naomi Gunawardena, Hyun Hyung An, Randall W. Veliquette, Edmund Carvalho, Sambit Dalui, Kaoru Takasaki, Eric Wafula, Deborah L. French, Giulia Pavani, Stella T. Chou

    Background: Blood bank identification of antibodies against high‐prevalence antigens remains a challenge due to the scarcity of antigen‐negative reagent red cells sourced from blood donors. The MAM antigen, encoded by EMP3 , is one such antigen associated with red cell alloimmunization and hemolytic disease of the fetus and newborn. Study Design and Methods: We used CRISPR‐Cas9 gene editing to generate an EMP3 knockout (EMP3KO) induced pluripotent stem cell (iPSC) line from a type O, Rh null parent line, enabling production of rare MAM‐negative red blood cells. Since a prior study suggested that loss of EMP3 may enhance erythroid proliferation, we hypothesized that EMP3KO could both yield a rare reagent cell and potentially improve erythroid expansion to support scalable production. Transcriptomic analysis allowed us to further investigate the effect of EMP3 loss in late erythroblasts. Results: EMP3KO cells differentiated efficiently into erythroid cells, showing >95% CD235/CD71 co‐expression and orthochromatic erythroblast morphology. Compared to unedited cells, no proliferative advantage was observed, contrasting with prior non‐isogenic cell models. Agglutination assays confirmed complete loss of MAM antigen and demonstrated the diagnostic utility for identifying MAM antibodies. Transcriptomic profiling of EMP3KO erythroblasts revealed expression of key erythroid genes, as well as regulators of proliferation and heme metabolism, was comparable to the parent line. Discussion: This study demonstrates that iPSC technology combined with gene editing can generate rare antigen‐negative RBCs for immunohematology applications. Beyond MAM, this platform offers a strategy to create additional rare RBC phenotypes, advancing precision transfusion medicine and improving antibody identification against high‐prevalence antigens.

  • Open Access

    Novel RHCE * cE ( 341A ) allele

    by Rébecca Voreux, Sunitha Vege, Odile Crépin, Raynald Flahaut, Céline Ricard, Gorka Ochoa‐Garay, Chloe Homich, Bruce S. Sachais, Lynsi Rahorst, Randall W. Velliquette, et al.